The Cancer Review brings you the latest news, expert analysis and research in the cancer industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

• Strategic insight into the future shape of cancer companies and markets

  
  

• The most significant cancer industry news compiled into one monthly update

  
  

• Expert analysis into the implications of the month's important cancer industry events

  
  

• Insight into the future shape of the market for players at all levels

  
  

• All the month's cancer stories in headline and summary form

  
  

Out of the dozens of topics covered in this month's review, the most important include:

* Novartis's Gleevec was granted a priority review by the FDA for possible use as a first-line treatment for newly diagnosed patients with Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase, the earliest stage of the disease.

* A US District Court jury found unanimously in favor of Genentech following the claims of Chiron's that Genentech had infringed a patent with their metastatic breast cancer drug, Herceptin.

• Not only keeps you updated about industry events - it also gives you opinion and insight

  
  

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

  
  

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

  
  

The most significant news in breast cancer R&D, compiled into one monthly update.

The most significant news in lung cancer R&D, compiled into one monthly update.

The most significant news in prostate cancer R&D, compiled into one monthly update.

The most significant news in colorectal cancer R&D, compiled into one monthly update.

The most significant news in other cancers, compiled into one monthly update including:

• Lymphoma and leukemia
  
  
  
• Brain cancer
  
  
  
• Ovarian cancer
  
  
  
• Liver cancers
  
  
  

Expert analysis of the implications of the month's important industry events

• Novartis: multiple roles for Gleevec
  
  
  
• AstraZeneca: a nail in the coffin of EGFr inhibitor hopes
  
  
  
• Novuspharma: lending a hand to Micromet
  
  
  
• Chiron/Genentech: battling on despite Herceptin ruling
  
  
  

Insight into the future shape of the market for players at all levels

• Tumors: breast most common in 2001
  
  
  
• Malignant melanoma: incidence to hit 77,000 in 2010
  
  
  

All the month's breast cancer news stories in headline and summary form

All the month's lung cancer news stories in headline and summary form

All the month's prostate cancer news stories in headline and summary form

All the month's colorectal cancer news stories in headline and summary form

All the month's other cancer news stories in headline and summary form